ENOV ENOVIS CORPORATION

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

The newest innovation in unloader braces is comfortable, easy to use and effective.

WILMINGTON, DE, Jan. 25, 2024 (GLOBE NEWSWIRE) --  Enovis™ Corporation (“Enovis” or the “Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today that its DJO, LLC subsidiary has launched its new DonJoy® ROAM™ OA knee brace for patients with osteoarthritis or other knee pain and instability.

ROAM OA is the latest innovation in unloader technology, unloading the pressure of unicompartmental osteoarthritis and shifting weight away from the affected knee to dynamically relieve pain, improve stability and help improve mobility. Designed for conservative care, preparation for surgery, or for postoperative knee protection, ROAM OA is ideal for a wide range of patients who want to maintain or increase activity.

“By the time osteoarthritis patients actually seek medical care, they usually have a significant amount of pain,” said orthopedic surgeon and pro sports team physician Brian J. Cole, MD. “Braces like the ROAM OA can provide the support and relief patients need to get back to the activities they love, without having surgery.”

Patient-friendly features make ROAM OA effective, comfortable and easy to use:

  • “Mag-align” magnetic clips help easily align the strap connection points to enhance patient confidence, even with eyesight or dexterity challenges.
  • “Set-and-Forget” technology allows patients to easily put the brace on and off without changing any provider settings.
  • BOA® Fit System lets patients easily dial up or down to adjust support and pain relief on demand.
  • Slim profile hinge design allows the brace to be worn confidently beneath clothing.
  • Dynamic strapping and unique condyle harness completely avoids sensitive skin in the popliteal (back of the knee) space, while providing comfortable pressure to activate proprioception on the opposite side of the knee with maximal unloading during extension.
  • Anti-migration technology uses soft silicone keeping the brace comfortably in place.
  • 2X Cool Technology fibers feel comfortable on the skin by keeping the surface 2 degrees cooler than the environment.
  • Unique design fits either left lateral and right medial, or vice versa, in only six SKUs compared to a traditional brace that needs as many as 56 SKUs to achieve the same range of patient fit.
  • Additionally, a custom-fabricated brace option addresses challenging fit needs with an optimal height setting, cuff sizing and strap lengths that provide maximum comfort and mitigate migration. Optional extension and flexion control meet each patient’s specific needs.

“ROAM OA represents the next generation of unloader knee braces for active patients with pain due to osteoarthritis or other causes," said Terry Ross, Group President of Enovis Prevention & Recovery. “It’s effective and easy for patients to use and easy for providers to prescribe, even for patients who would otherwise need a customized device.”

For more information about the ROAM OA knee brace, visit .





About Enovis™

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuel active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .



Brian J. Cole, MD, MBA is a consultant for DJO, LLC.

BOA® is a registered trademark of Boa Technology, Inc.





Investor Relations Contact

Kyle Rose

Vice President, Investor Relations

Enovis Corporation





Media Contact

Leda Buster

Director of Marketing Communications, Bracing and Supports

Enovis Corporation

 



Attachment



EN
25/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results

Update: Enovis Announces Fourth Quarter and Full Year 2025 Results Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31...

 PRESS RELEASE

Enovis Announces Fourth Quarter and Full Year 2025 Results

Enovis Announces Fourth Quarter and Full Year 2025 Results Continued commercial momentum with full year 2025 sales growth of 7% on a reported basis and 6% organically Full year 2025 Reconstructive sales grew 10% Y/Y on a reported basis and 8% on an organic basis Full year 2025 Prevention & Recovery sales grew 4% Y/Y on a reported and organic basis Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2025. ...

 PRESS RELEASE

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health,...

Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. About Enovis Enovis™ (NYSE: ENOV) is a global medical technology innovator dedicated to improving lives by developing clinically differentiated solution...

 PRESS RELEASE

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Ca...

Enovis to Host Fourth Quarter and Full Year 2025 Results Conference Call on February 26th Dallas, TX, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its fourth quarter and full year 2025 financial results on Thursday, February 26th, 2026 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. The live webcast and a presentation related to the call will be accessible from the "Investors" section of Eno...

 PRESS RELEASE

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Confer...

Enovis to Participate in the 44th Annual J.P. Morgan Healthcare Conference Dallas, TX, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will meet with investors at the 44th Annual J.P. Morgan Healthcare Conference with a presentation scheduled for Monday, January 12th, 2026, at 4:30 p.m. PST (7:30 p.m. EST). A link to the live audio webcast, as well as a copy of the accompanying presentation slides and a replay of this event, will be available on the company’s website () at...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch